Equities
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)12.80
  • Today's Change-0.86 / -6.30%
  • Shares traded3.53m
  • 1 Year change-50.39%
  • Beta1.6539
Data delayed at least 15 minutes, as of May 03 2024 09:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Zai Lab Ltd is a holding company mainly engaged in the biopharmaceutical field. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including oncology, autoimmune and infectious diseases fields. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include Niraparib (ZL-2306), ZL-2103, ZL-1101 and others.

  • Revenue in HKD (TTM)2.08bn
  • Net income in HKD-2.61bn
  • Incorporated2013
  • Employees2.18k
  • Location
    Zai Lab Ltd4560 Jinke Road, Bldg. 1, 4/F, PudongSHANGHAI 201210ChinaCHN
  • Phone+86 2 161632588
  • Fax+86 2 161632570
  • Websitehttps://www.zailaboratory.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Shanghai Henlius Biotech Inc5.82bn589.20m9.02bn3.64k15.363.819.241.551.081.0810.674.350.57311.959.101,600,654.005.80-8.5912.47-14.1472.6471.7710.12-27.370.37866.480.6512--67.82273.51178.53--49.14--
Cansino Biologics Inc372.48m-1.60bn9.21bn1.49k--0.944--24.73-6.48-6.481.5123.040.03322.370.4619249,318.30-18.93-4.27-26.69-5.60-253.78---569.97-27.721.86--0.3381---66.52213.94-63.04--30.60--
Keymed Biosciences Inc382.10m-387.78m9.96bn897.00--3.09--26.06-1.49-1.491.4511.520.09060.731426.14425,974.80-9.16---10.05--89.59---101.04--9.18--0.123--253.87---16.63------
InnoCare Pharma Ltd796.95m-681.19m10.49bn1.09k--1.22--13.16-0.4039-0.40390.47234.370.0731.393.39731,814.40-6.38-13.41-8.08-15.3682.6185.99-87.42-172.164.13--0.1582--18.09240.3628.80--66.20--
Lepu Biopharma Co Ltd243.17m-23.84m10.64bn429.00--10.99136.6743.74-0.0144-0.01440.14650.58320.09171.061.62566,840.30-1.23---1.91--87.45---13.45--0.72010.13880.4549--1,347.16--96.79------
AIM Vaccine Co Ltd1.28bn-1.40bn10.75bn1.62k--2.74--8.39-1.16-1.161.063.25------789,028.10--------75.88---164.24--0.7583-14.040.3158---6.06---307.07------
Luye Pharma Group Ltd6.63bn574.73m11.36bn5.27k19.670.84018.481.710.15350.15351.783.590.2472.423.601,257,859.002.172.803.564.4568.4470.538.7810.391.213.100.393111.822.703.50-11.94-16.39-14.05--
SciClone Pharmaceuticals (Holdings) Ltd3.41bn1.21bn11.37bn1.05k9.753.2214.893.341.861.865.245.620.75853.563.833,243,032.0026.9727.0933.3436.3274.6776.0635.5535.434.5027.950.01--14.7617.5031.1615.96----
Yichang Hec Changjiang Pharmactcl Co Ltd6.79bn2.15bn11.44bn4.62k5.321.344.721.682.442.447.729.730.51113.624.001,470,855.0015.078.0324.4611.8179.2179.9729.4820.801.309.320.2475--68.0820.182,501.2416.15----
Zai Lab Ltd2.08bn-2.61bn12.70bn2.18k--2.00--6.09-2.70-2.702.166.400.23642.515.38---29.66-37.72-34.97-42.7264.0864.75-125.46-282.444.41--0.00--24.03360.0324.51---3.45--
SSY Group Ltd6.46bn1.32bn14.19bn5.60k10.802.058.122.200.44270.44272.172.330.56373.003.011,154,109.0011.5910.5115.5814.0356.0158.7220.5718.621.6029.610.31738.560.45059.1017.447.663.9413.56
Simcere Pharmaceutical Group Ltd7.13bn771.29m14.82bn7.03k19.631.9113.422.080.28940.28942.732.980.61063.532.651,014,714.006.6010.178.9415.6075.4378.8210.8017.501.870.97420.165246.684.497.92-23.22-0.521323.93--
Grand Pharmaceutical Group Ltd10.53bn1.88bn16.12bn10.53k8.481.057.041.530.53560.53563.004.330.46922.9410.26999,581.408.4510.0911.6614.0161.9661.9718.0022.350.981922.960.183126.9410.1212.06-9.5921.415.6924.77
Data as of May 03 2024. Currency figures normalised to Zai Lab Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

21.37%Per cent of shares held by top holders
HolderShares% Held
Wellington Management Co. LLPas of 16 Feb 202460.81m6.13%
The Vanguard Group, Inc.as of 05 Apr 202437.90m3.82%
Credit Suisse Asset Management (Schweiz) AGas of 29 Feb 202423.29m2.35%
Wellington Management International Ltd.as of 16 Feb 202420.25m2.04%
UBS Asset Management Switzerland AGas of 01 Feb 202418.93m1.91%
Baillie Gifford & Co.as of 31 Mar 202415.81m1.59%
BlackRock Fund Advisorsas of 04 Apr 202415.73m1.59%
Bosera Asset Management Co., Ltd.as of 31 Dec 20227.63m0.77%
BlackRock Advisors (UK) Ltd.as of 04 Apr 20246.21m0.63%
Capital Research & Management Co. (World Investors)as of 19 Feb 20245.43m0.55%
More ▼
Data from 31 Dec 2023 - 22 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.